Dr. Ronan Kelly is the Medical Director of Global Oncology for Johns Hopkins International and the Director of the Gastro-esophageal Cancer Therapeutics Program at the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.
As a thoracic oncologist, Dr. Kelly is committed to the understanding of genomic and epigenomic alterations in gastro-esophageal and lung cancers. Dr. Kelly performs translational research encompassing the discovery and the development of new epigenetic, genetic and immunotherapeutic approaches in the detection, diagnosis, prevention and treatment of thoracic malignancies.
Dr. Kelly and his colleagues at Johns Hopkins have been studying the cost-effectiveness of newly approved oncology drugs. He has recently completed a study where the costs of chemotherapy have been provided to patients and their doctors at the time of prescribing. He is actively working with Johns Hopkins affiliates throughout the world to improve the quality of cancer care.
Dr. Kelly received his initial medical training at the Royal College of Surgeons in Ireland, graduating with honors. Subsequently, he earned a Master’s degree in Business dministration from University of College Dublin, with a focus on health economics and drug costs. He worked at the National Cancer Institute for four years prior to joining Hopkins in 2011.